[go: up one dir, main page]

AR118898A1 - Dominios variantes para multimerizar proteínas y su separación - Google Patents

Dominios variantes para multimerizar proteínas y su separación

Info

Publication number
AR118898A1
AR118898A1 ARP200101330A ARP200101330A AR118898A1 AR 118898 A1 AR118898 A1 AR 118898A1 AR P200101330 A ARP200101330 A AR P200101330A AR P200101330 A ARP200101330 A AR P200101330A AR 118898 A1 AR118898 A1 AR 118898A1
Authority
AR
Argentina
Prior art keywords
proteins
immunoglobulin
separation
variant domains
multimerizing
Prior art date
Application number
ARP200101330A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Peter Brian Silverman
Richard Bonneau
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of AR118898A1 publication Critical patent/AR118898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a medios y métodos para producir y aislar proteínas inmunoglobulinas que comprenden un primer y un segundo polipéptido de inmunoglobulina, en particular medios y métodos para producir y separar proteínas que comprenden un primer y un segundo polipéptido de inmunoglobulina. Mediante la inclusión de variaciones en los aminoácidos, y dominios de separación variantes de una célula que produce la proteína inmunoglobulina deseada, se puede separar de las mezclas de proteínas inmunoglobulinas una proteína inmunoglobulina deseada tal como se produjo.
ARP200101330A 2019-05-09 2020-05-08 Dominios variantes para multimerizar proteínas y su separación AR118898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09

Publications (1)

Publication Number Publication Date
AR118898A1 true AR118898A1 (es) 2021-11-10

Family

ID=66476558

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101330A AR118898A1 (es) 2019-05-09 2020-05-08 Dominios variantes para multimerizar proteínas y su separación

Country Status (17)

Country Link
US (1) US20210054049A1 (es)
EP (1) EP3966238A2 (es)
JP (2) JP7760377B2 (es)
KR (1) KR20220017909A (es)
CN (2) CN114430745A (es)
AR (1) AR118898A1 (es)
AU (2) AU2020268684B2 (es)
BR (1) BR112021022405A2 (es)
CA (1) CA3139402A1 (es)
IL (1) IL287928A (es)
MA (1) MA55884A (es)
MX (1) MX2021013646A (es)
NZ (1) NZ782091A (es)
PH (1) PH12021552833A1 (es)
SG (1) SG11202112399PA (es)
TW (1) TW202108613A (es)
WO (1) WO2020226502A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200139189A (ko) * 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
WO2022133191A2 (en) * 2020-12-18 2022-06-23 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
EP4642811A1 (en) 2022-12-27 2025-11-05 Merus N.V. Method for generating bispecific proteins
WO2025221138A1 (en) 2024-04-15 2025-10-23 Merus N.V. Cd3 binding domains
WO2025230410A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230409A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2026013015A1 (en) 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
EP1554392A4 (en) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF NEW NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH WIDE CROSS-REACTIVITY USING SEQUENTIAL ANTIGEN PANNING OF PHAG DISPLAY LIBRARIES
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
UA87979C2 (ru) * 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
DK2009101T3 (en) * 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
JP5334319B2 (ja) * 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
KR20200052383A (ko) * 2011-03-25 2020-05-14 아이크노스 사이언스 에스. 아. 헤테로 이량체 면역글로불린
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3611187A1 (en) * 2011-10-10 2020-02-19 Xencor, Inc. A method for purifying antibodies
KR102398736B1 (ko) * 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
WO2013157953A1 (en) * 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN104045714B (zh) * 2013-03-14 2019-01-11 南京金斯瑞生物科技有限公司 曲妥珠单抗突变体IgG及其应用
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
BR112018075253A2 (pt) * 2016-06-10 2019-04-30 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas com lisina
WO2017218698A1 (en) * 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
CA3068929A1 (en) 2017-07-06 2019-01-10 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
IL271832B2 (en) 2017-07-06 2025-07-01 Merus Nv Bispecific anti pd1-anti tim3 antibodies and uses thereof
CA3068933A1 (en) 2017-07-06 2019-01-10 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
FI3665198T3 (fi) 2017-08-09 2025-04-25 Merus Nv EGFR:ää ja cMET:tä sitovia vasta-aineita
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
KR20200139189A (ko) 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途

Also Published As

Publication number Publication date
SG11202112399PA (en) 2021-12-30
KR20220017909A (ko) 2022-02-14
AU2025208511A1 (en) 2025-08-14
NZ782091A (en) 2025-08-29
TW202108613A (zh) 2021-03-01
MX2021013646A (es) 2022-01-31
JP7760377B2 (ja) 2025-10-27
WO2020226502A3 (en) 2021-02-04
AU2020268684A1 (en) 2021-12-09
JP2025120179A (ja) 2025-08-15
BR112021022405A2 (pt) 2022-04-19
JP2022534674A (ja) 2022-08-03
EP3966238A2 (en) 2022-03-16
IL287928A (en) 2022-01-01
CN114702587A (zh) 2022-07-05
WO2020226502A9 (en) 2022-03-03
US20210054049A1 (en) 2021-02-25
WO2020226502A2 (en) 2020-11-12
PH12021552833A1 (en) 2023-01-16
AU2020268684B2 (en) 2025-07-03
CA3139402A1 (en) 2020-11-12
CN114430745A (zh) 2022-05-03
MA55884A (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
AR118898A1 (es) Dominios variantes para multimerizar proteínas y su separación
MX2025003310A (es) Integracion dirigida de acidos nucleicos
AR120511A2 (es) Producción de proteínas heteromultiméricas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX2018009989A (es) Composiciones funcionales derivadas de frijol mungo.
MX389073B (es) Método para producir una proteína de fusión de anticuerpo.
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
HRP20191446T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
BR112012025326A2 (pt) "extração seletiva de proteínas de algas de água salgada"
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
UY37970A (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
MX378520B (es) Metodo para extraer proteinas solubles de biomasa de microalgas.
MX2018009331A (es) Metodos para extraer proteinas a partir de un material a base de sangre.
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
MX2019007316A (es) Eliminacion de acidos nucleicos y fragmentos de los mismos de un material de biomasa.
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
HRP20231139T1 (hr) Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
WO2018120843A9 (zh) 一种三功能分子及其应用
BR112018005464A2 (pt) expressão de proteínas contendo fc
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina